NEK2 and non-small cell lung carcinoma: In NSCLC patients with EGFR mutations, EGFR mutations can activate the ERK signal transduction pathway and then induce the high expression of NEK2, which can promote the rapid development of the cell cycle and the rapid proliferation of NSCLC cells, resulting in poor prognosis40.